Tension‐Free Vaginal Tape‐SECUR Procedure for the Treatment of Female Stress Urinary Incontinence: 3‐Year Follow‐Up Results. Issue 1 (28th October 2013)

• Record Type: Journal Article
• Authors: LEE, Ha Na; LEE, Sin‐Woo; LEE, Young‐Suk; LEE, Seo Yeon; LEE, Kyu‐Sung
• Is Part Of: LUTS. Volume 7:Issue 1(2015)
• Page Start: 9
• Page End: 16
• Publication Date: 2013-10-28
• Subjects: Urology -- Periodicals; Urologic Diseases -- Periodicals; Urinary Tract Physiological Phenomena -- Periodicals; 616.62
• DOI: 10.1111/luts.12040
• Languages: English
• ISSNs: 1757-5664

Abstract

<abstract abstract-type="main" id="luts12040-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="luts12040-sec-0001" sec-type="section"> <title>Objectives</title> <p id="luts12040-para-0001">To assess the efficacy and complications associated with the use of the tension‐free vaginal tape (TVT)‐Secur system device for the treatment of female stress urinary incontinence (SUI) based on a 3‐year follow‐up.</p> </sec> <sec id="luts12040-sec-0002" sec-type="section"> <title>Methods</title> <p id="luts12040-para-0002">Women with SUI were randomly allocated to either the U‐ or H‐type groups depending on the TVT‐Secur approach used. Patients were questioned about continence and satisfaction 1, 2, and 3 years after surgery. Patients were assessed postoperatively by questionnaires including Sandvik, Incontinence Quality of Life (I‐QoL), Bristol Female Lower Urinary Tract Symptoms‐Scored Form (BF‐LUTS), incontinence visual analogue scale (I‐VAS), and benefit, satisfaction, and willingness to continue questionnaire. Cure was regarded as no leakage on the Sandvik questionnaire.</p> </sec> <sec id="luts12040-sec-0003" sec-type="section"> <title>Results</title> <p id="luts12040-para-0003">A total of 115 patients with SUI were included in this study (U‐type: 53, H‐type: 62). A total of 102 patients were followed‐up for 3 years (U‐type: 47, H‐type: 55). The overall cure rate at the 1‐, 2‐, and 3‐year follow‐ups was 87.8, 83.0, and 79.4%, respectively, and there was no difference in the cure rate between the U‐and H‐type approaches. Approximately 83.4 and 83.3% of patients were satisfied with the surgical outcome at the 1‐ and 3‐year follow‐ups. I‐QoL, BFLUTS‐SF, and I‐VAS were improved from baseline regardless of the approach used at the 1‐ and 2‐year follow‐ups. Complications included intraoperative vaginal wall perforation (three cases), voiding difficulties such as immediate postoperative retention, and urgency episodes.</p> </sec> <sec id="luts12040-sec-0004" sec-type="section"> <title>Conclusions</title> <p id="luts12040-para-0004">Both U‐ and H‐type approaches of TVT‐Secur for the treatment of female SUI remains efficacious, safe, and satisfactory for up to 3 years after surgery.</p> </sec> </abstract>